CUE vs LEN · rev $9.3M vs rev $34.19B
Cue Biopharma (CUE) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
CUE currently screens at market cap $59.5M. LEN currently screens at market cap $0.
Not investment advice. Open the CUE and LEN stock pages for the full models.
Not investment advice.